Christine Cook, MD
Pulmonary Disease · Overland Park, KSNPI 1952797052
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $603 and has fallen 86.3% since, to $83 in 2025. That places this record below the midpoint for pulmonary disease clinicians in KS, where the typical reported total is $1,991.
Across 51 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$207
- AbbVie$155
- Actelion Pharmaceuticals US, Inc.$141
- Boehringer Ingelheim$110
- GSK$81
- Amgen$50
- plus $400 from 14 others
What the payments were for
- Food & beverage$1,05592%
- Education$898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $207 |
| AbbVie | 7 | $155 |
| Actelion Pharmaceuticals US, Inc. | 4 | $141 |
| Boehringer Ingelheim | 6 | $110 |
| GSK | 5 | $81 |
| Amgen | 2 | $50 |
| Grifols USA, LLC | 2 | $48 |
| Sanofi | 2 | $48 |
| Intuitive Surgical | 1 | $41 |
| Vapotherm Inc | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Mylan Specialty L.p. | 2 | $30 |
| Pfizer | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Inogen, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
How this compares
$1,144 in reported general payments places this provider in the 40th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 223 | $172,751 |
| Dupixent PenDupilumab | 23 | $86,161 |
| Spiriva RespimatTiotropium Bromide | 63 | $42,842 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $41,239 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $39,952 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $30,303 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $27,526 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 73 | $9,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 298 | $8,756 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 48 | $7,592 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,934 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,184 |
| Ventolin HfaAlbuterol Sulfate | 12 | $782 |
| Azithromycin | 38 | $734 |
| Prednisone | 126 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $81 | $244,293349 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $110 | $70,367114 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $207 | $42,88664 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Overland Park
- Brietta ForbesOverland Park$10K
- Mitchell TenerOverland Park$6K
- Jason FieserOverland Park$6K
- James KaplanOverland Park$4K
- Daniel BalmacedaOverland Park$3K
- Trenton NauserOverland Park$1K
- John NelsonOverland Park$1K
- Scott EveloffOverland Park$903
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.